BOSTON--(BUSINESS WIRE)--Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, today announced it has raised an oversubscribed $5.2 million seed ...
Brian McKernan joins as CEO to further advance Predicta’s clinical impact, including its non-invasive diagnostic for Multiple Myeloma “It’s an honor to join Predicta and our strong team of leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results